Values First Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Values First Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,754	Closed	-$27K	–	225
2024 Q3	$27K	Buy	+1,754	New	+$29.3K	0.01%	261

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Values First Advisors's ACAD Position: Q4 2024 in Review

Values First Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 1,754 shares — an estimated $27K sold.

Values First Advisors first reported a position in ACAD in Q3 2024 and held it in 1 quarter. The position peaked at $27K in Q3 2024. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

Values First Advisors reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Values First Advisors sold 1,754 Acadia Pharmaceuticals shares in Q4 2024, an estimated $27K.
Values First Advisors first reported a position in Acadia Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Values First Advisors's Acadia Pharmaceuticals position peaked at $27K in Q3 2024.
296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on Values First Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.